VCP and breast cancer: Subsequently, the same authors maintained that low levels of pSer784-VCP should be considered a predictive biomarker for patients with breast cancer who are treated with genotoxic therapies and that patients with higher levels of pSer784-VCP might benefit from chemosensitization DDR kinase family inhibitors already in clinical use [80].